5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

BLU Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.26%

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$0.00

BELLUS Health Insider Trading History Chart

BELLUS Health Share Price & Price History

C^$19.48

▼ -0.02 (-0.10%)

As of 06/30/2023 12:59 AM ET

Days: 30 | 90 | 365

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

BELLUS Health Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2022	Pierre Larochelle	Director	Sell	35,667	C$12.59	C$448,976.20	131,389
11/18/2022	Joseph Rus	Director	Sell	35,643	C$12.14	C$432,559.88
3/22/2022	Francois Desjardins	Senior Officer	Sell	14,053	C$8.47	C$118,989.56	81,722

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

SEC Filings (Institutional Ownership Changes) for BELLUS Health (TSE:BLU)

90.41% of BELLUS Health stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Today's Range

Now: C$19.48

C$19.24

C$19.61

50 Day Range

MA: C$19.48

C$19.48

52 Week Range

Now: C$19.48

C$8.58

C$19.90

Volume

28,666 shs

Average Volume

59,471 shs

Market Capitalization

C$2.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of BELLUS Health?: BELLUS Health's top insider shareholders include:
Pierre Larochelle (Director)
Joseph Rus (Director)
Learn More about top insider investors at BELLUS Health.

The #1 Crypto for 2024

From InvestorPlace | Ad